Identification of early neurodegenerative pathways in progressive multiple sclerosis

  • Max Kaufmann (Shared first author)
  • Anna-Lena Schaupp (Shared first author)
  • Rosa Sun
  • Fabian Coscia
  • Calliope A Dendrou
  • Adrian Cortes
  • Gurman Kaur
  • Hayley G Evans
  • Annelie Mollbrink
  • José Fernández Navarro
  • Jana K Sonner
  • Christina Mayer
  • Gabriele C DeLuca
  • Joakim Lundeberg
  • Paul M Matthews
  • Kathrine E Attfield
  • Manuel A Friese
  • Matthias Mann
  • Lars Fugger

Abstract

Progressive multiple sclerosis (MS) is characterized by unrelenting neurodegeneration, which causes cumulative disability and is refractory to current treatments. Drug development to prevent disease progression is an urgent clinical need yet is constrained by an incomplete understanding of its complex pathogenesis. Using spatial transcriptomics and proteomics on fresh-frozen human MS brain tissue, we identified multicellular mechanisms of progressive MS pathogenesis and traced their origin in relation to spatially distributed stages of neurodegeneration. By resolving ligand-receptor interactions in local microenvironments, we discovered defunct trophic and anti-inflammatory intercellular communications within areas of early neuronal decline. Proteins associated with neuronal damage in patient samples showed mechanistic concordance with published in vivo knockdown and central nervous system (CNS) disease models, supporting their causal role and value as potential therapeutic targets in progressive MS. Our findings provide a new framework for drug development strategies, rooted in an understanding of the complex cellular and signaling dynamics in human diseased tissue that facilitate this debilitating disease.

Bibliographical data

Original languageEnglish
ISSN1097-6256
DOIs
Publication statusPublished - 07.2022

Comment Deanary

© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

PubMed 35726057